ENTA
Enanta Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$14.08
+0.43%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 65.3M | 65.3M | 67.6M | 79.2M | 86.2M |
| Cost of Revenue | 1.2M | 4.6M | — | — | — |
| Gross Profit | 64.0M | 60.7M | 67.6M | 79.2M | 86.2M |
| Operating Expenses | |||||
| R&D Expense | 86.2M | 106.7M | 131.5M | 163.5M | 164.5M |
| SG&A Expense | 37.7M | 43.9M | 57.9M | 52.9M | 45.5M |
| General & Admin Expense | 37.7M | 43.9M | 57.9M | 52.9M | 45.5M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (1.2M) | (4.6M) | — | — | — |
| Total Operating Expenses | 122.8M | 146.1M | 189.3M | 216.4M | 210.0M |
| Cost and Expenses | 124.0M | 150.7M | 189.3M | 216.4M | 210.0M |
| Operating Income (EBIT) | (58.7M) | (85.3M) | (121.7M) | (137.2M) | (123.8M) |
| Non-Operating | |||||
| Interest Income | 6.6M | 9.5M | 14.8M | 11.4M | 1.6M |
| Interest Expense | 12.9M | 7.7M | 10.9M | 5.1M | — |
| Net Interest Income | (6.3M) | 1.8M | 3.8M | 6.2M | 1.6M |
| Other Non-Op Income/Expense | (4.4M) | 1.8M | 3.9M | 6.2M | 1.7M |
| Non-Operating Income (excl Interest) | (8.5M) | (9.5M) | (14.8M) | (11.4M) | (1.7M) |
| EBT (Pre-Tax Income) | (63.1M) | (83.5M) | (117.8M) | (131.0M) | (122.2M) |
| Income Tax Expense | 99.0K | (1.7M) | (1.7M) | 2.8M | (433.0K) |
| Bottom Line | |||||
| Net Income | (63.2M) | (81.9M) | (116.0M) | (133.8M) | (121.8M) |
| Earnings from Cont. Ops | (63.2M) | (81.9M) | (116.0M) | (133.8M) | (121.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (63.2M) | (81.9M) | (116.0M) | (133.8M) | (121.8M) |
| Per Share | |||||
| Basic EPS | ($2.41) | ($3.84) | ($5.48) | ($6.38) | ($5.91) |
| Diluted EPS | ($2.41) | ($3.84) | ($5.48) | ($6.38) | ($5.91) |
| Revenue Per Share | $2.24 | $3.06 | $3.20 | $3.78 | $4.18 |
| Shares | |||||
| Basic Shares Outstanding | 29.1M | 21.3M | 21.2M | 21.0M | 20.6M |
| Diluted Shares Outstanding | 29.1M | 21.3M | 21.2M | 21.0M | 20.6M |
| Profitability Metrics | |||||
| EBITDA | (46.5M) | (70.8M) | (104.5M) | (123.5M) | (119.2M) |
| D&A | 3.7M | 5.1M | 2.3M | 2.4M | 3.0M |
| EBIT | (50.2M) | (75.9M) | (106.8M) | (125.8M) | (122.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026